TFF Pharmaceuticals Inc

TFF Pharmaceuticals — Corporate Update (August 2024)

14 slides from TFF Pharmaceuticals's corporate update, Aug 6, 2024

  1. Slide 1: TFF TAC Updated Phase 2 Clinical Data Release

    1 NASDAQ: TFFP TFF TAC Updated Phase 2 Clinical Data Release August 6, 2024 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, “TFF Pharmaceuticals”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “con

  3. Slide 3: TFF TAC delivers tacrolimus directly to the lung while limiting systemic exposure

    3 TFF TAC delivers tacrolimus directly to the lung to drive efficacy while limiting systemic exposures thus toxicities 1. Costa, Benvenuto, and Sonett, Best Practice & Research Clinical Anesthesiology , 2017 2. Lung levels were compared with blood levels in the 28 - day and 26 - week toxicology stud

  4. Slide 4: TFF TAC: Phase 2 Study (TFF-T2-001) Design in Lung Transplant Patients

    4 TFF TAC: Phase 2 Study (TFF - T2 - 001) Design in Lung Transplant Patients Tac dosing • Design : Open label study of TFF TAC lung transplant recipients requiring reduced tac blood levels due to renal toxicity • Duration : Part A : 12 weeks; Part B : optional long - term extension • Endpoints : Saf

  5. Slide 5: Data Release Highlights

    Data Release Highlights • Patient Enrollment Has Accelerated with 13 Patients Now Enrolled in Phase 2 Trial • TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved ~84% of the oral trough blood levels leading to diminished drug burden • 9 out of 9 (100%) Patients Who Com

  6. Slide 6: TFF TAC (TFF-T2-001) Clinical Data Update

    TFF TAC (TFF - T2 - 001) Clinical Data Update 6

  7. Slide 7: TFF TAC: Baseline Characteristics and Demographics

    TFF TAC: Baseline Characteristics and Demographics Data is from TFF - T2 - 001 pre - database lock; Data cut off date of 7/23/24 includes 12 patients; one additional patient enrolled by 8/6/24 7 CLAD: chronic lung allograft dysfunction W: white; F: female; M: male; NH: Native Hawaiian N/A: not avail

  8. Slide 8: TFF TAC: Total Patient Exposure

    TFF TAC: Total Patient Exposure 200 150 100 50 0 250 300 350 Weeks Pt 12 Pt 11 Pt 10 Pt 9 Pt 8 Pt 7 Pt 6 Pt 5 Pt 4 Pt 3 Pt 2 Pt 1 Cumulative Data is from TFF - T2 - 001 pre - database lock; Data cut off date of 7/23/24 includes 12 patients; one additional patient enrolled by 8/6/24 8 Total patient e

  9. Slide 9: TFF TAC at a fraction of the oral dose maintains systemic exposure

    9 Variability in metabolism contributes to individualized dosing with oral Tacrolimus and TFF TAC. NA: not applicable; Blank indicates data not yet available Data is from TFF - T2 - 001 pre - database lock; Data cut off date of 7/23/24 includes 12 patients; one additional patient enrolled by 8/6/24

  10. Slide 10: Stable Trough Tacrolimus Blood Levels: TFF TAC / Oral Tacrolimus

    Stable Trough Tacrolimus Blood Levels: TFF TAC / Oral Tacrolimus Mean Stable TFF TAC Dose / Mean Stable Oral Tacrolimus Dose ~84% ~20% n=12 Efficacy • 13 patients transitioned from oral tacrolimus to TFF TAC; transition data available on 11 patients • Among 10 patients transitioned to TFF TAC per pr

  11. Slide 11: 85% reduction in abnormally expressed rejection-related gene sets

    TFF TAC: 85% reduction in the number of abnormally expressed rejection - related gene sets after treatment with TFF TAC Abnormal Slightly Abnormal Normal 1.625 1.750 3.625 Number of rejection - related gene sets on oral tacrolimus 0.250 1.625 5.125 Number of rejection - related gene sets on TFF TAC

  12. Slide 12: TFF TAC Prevents Formation of Donor-Specific Antibodies

    12 TFF TAC Prevents Formation of Donor - Specific Antibodies Donor - Specific Antibody ( DSA): • Donor - specific antibodies are generated when there is insufficient immune suppression systemically allowing the formation of antibodies in the lymph nodes against the transplanted (donor) organ • Donor

  13. Slide 13: Data Release Highlights

    Data Release Highlights • Patient Enrollment Has Accelerated with 13 Patients Now Enrolled in Phase 2 Trial • TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved ~84% of the oral trough blood levels leading to diminished drug burden • 9 out of 9 (100%) Patients Who Com

  14. Slide 14: Thank You

    PHARMACEUTICALS THANK YOU

TFF Pharmaceuticals — Corporate Update (August 2024) on 6ix